X4 PHARMACEUTICALS INC. - COMMON STOCK

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 4 2022 15:05:00 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

17 3 2022 05:05:00 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals to Announce Fourth Quarter 2021 Financial Results and Host a Conference Call and Webcast on March 17, 2022

08 3 2022 07:00:03 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals to Present at March Investor Conferences

03 3 2022 07:00:01 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 3 2022 07:00:01 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 2 2022 15:05:00 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals to Present at B. Riley Securities Oncology Investor Conference

19 1 2022 07:00:01 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 1 2022 15:05:00 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals Presents New Clinical and Scientific Data at 2021 ASH Annual Meeting Supporting Broader Potential for Mavorixafor in the Treatment of Primary Immunodeficiencies

13 12 2021 07:00:01 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals Presents New Clinical Data at ASH 2021 Further Supporting Potential of Mavorixafor + Ibrutinib to Treat Patients with Double-Mutation Waldenström’s Macroglobulinemia

11 12 2021 08:00:00 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals to Host Virtual Seminar “Understanding Primary Immunodeficiencies” to Highlight Broadening Market Opportunities for Mavorixafor

02 12 2021 05:05:00 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 12 2021 15:05:00 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in Stifel’s Virtual Healthcare Conference

10 11 2021 07:00:02 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals to Have Strong Presence at ASH 2021 with Seven Accepted Abstracts Highlighting New Clinical and Scientific Data; Company Reports Third Quarter Financial Results

04 11 2021 08:01:00 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 11 2021 15:05:00 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 4, 2021

25 10 2021 07:00:01 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals Expands Commercial Leadership Expertise with Appointment of Françoise de Craecker to Board of Directors and Karolyn Park as Vice President, U.S. Commercial

19 10 2021 07:00:02 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals Completes Enrollment in Phase 3 Mavorixafor Trial in Patients with WHIM Syndrome

04 10 2021 07:00:00 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 10 2021 15:05:00 提供 Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in Upcoming Investor Conferences

15 9 2021 15:05:00 提供 Nasdaq GlobeNewswire